科前生物(688526.SH):2025年三季报净利润为3.38亿元

Core Insights - The company reported a total revenue of 738 million yuan for Q3 2025, ranking 7th among disclosed peers [1] - The net profit attributable to shareholders was 338 million yuan, with a net cash inflow from operating activities of 316 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 12.21%, an increase of 0.84 percentage points from the previous quarter [3] - The gross profit margin is 66.96%, a decrease of 0.32 percentage points compared to the previous quarter, with a return on equity (ROE) of 8.10% [4] - The diluted earnings per share (EPS) is 0.72 yuan [5] - The total asset turnover ratio is 0.16 times, ranking 10th among disclosed peers, while the inventory turnover ratio is 1.87 times, ranking 9th, which is a decrease of 0.01 times year-on-year, reflecting a 0.51% decline compared to the same period last year [5] Shareholder Structure - The number of shareholders is 9,713, with the top ten shareholders holding a total of 348 million shares, accounting for 74.56% of the total share capital [5] - The top shareholders include Wuhan Huazhong Agricultural University Asset Management Co., Ltd. (16.7%), Chen Huan Chun (15.2%), and Jin Mei Lin (7.87%) [5]